Resection improves survival rate in advanced melanoma cases

04/16/2013 | SkinAndAllergyNews.com

Patients with advanced melanoma treated with surgical resection along with the drug ipilimumab had a 5-year melanoma-specific survival rate of 51% and a median overall survival duration of 60 months, according to researchers at the John Wayne Cancer Institute in Santa Monica, Calif. A 2012 study found a 7% survival rate for advanced melanoma patients treated with systemic medical therapy alone.

View Full Article in:

SkinAndAllergyNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA